Adaptimmune Therapeutics PLC (NASDAQ:ADAP) CEO James Noble and Co-Founder Helen Tayton-Martin tell Proactive Investors the US and UK-based cell therapy company is kicking off its SURPASS clinical trial with its SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform, that allows T-cells to target and destroy solid tumor cancers.
Noble and Tayton-Martin say the SURPASS trial will now begin enrolling up to 30 patients across multiple solid tumor indications in the US, hoping to complete enrollment at year end.
